Cerus

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cerus excels in Q4 with record growth and strategic milestones

Cerus delivered a strong performance in Q4 2022, driven by the success of the INTERCEPT Blood System and robust product revenue growth.
While facing challenges in inventory management and international expansion, the company's focus on innovation and upcoming milestones position it for future growth.
Opportunities in regulatory submissions, market expansion, and achieving cash flow breakeven in 2023 underscore Cerus' potential for sustained success and market leadership.

Cerus reports Q1 revenue dip, eyes China growth opportunities

Cerus navigated Q1 with a focus on financial stability, product adoption, and global market expansion. Despite revenue challenges, the company's strategic initiatives and successful debt refinancing position it for future growth. Addressing inventory management, label expansion, and market-specific hurdles will be key to unlocking opportunities.

Cerus (CERS) reports robust Q2 performance amidst growth challenges

Cerus delivered a strong performance in Q2, marked by revenue growth, improved margins, and effective cost management.
While facing challenges in U.S. customer ordering patterns and market penetration, the company remains well-positioned for growth.
With a focus on operational efficiency, product development, and market expansion, Cerus is poised to capitalize on growth opportunities.
The company's financial strength, coupled with strategic initiatives, sets a positive trajectory for continued progress and success.

Cerus reports robust Q3 sales, adjusts revenue guidance for 2023

Cerus shows strong sales growth, positive market sentiment, and progress in key trials. Challenges include revenue guidance adjustment due to delayed sales agreement. Opportunities lie in expanding product demand and achieving EBITDA breakeven.

Cerus surpasses 16 million kits sold, expects double-digit growth

Cerus delivered a strong performance in Q4 2023, surpassing 16 million kits sold and achieving positive non-GAAP adjusted EBITDA for the first time.
The company's focus on the platelet franchise and IFC business yielded growth, setting the stage for continued expansion in 2024.
While facing challenges in revenue expectations and market competition, Cerus remains well-positioned to capitalize on growth opportunities.
Guidance for 2024 indicates a positive outlook with expectations of sustained growth in the INTERCEPT platelet business and IFC revenue.

Cerus reports robust Q1 earnings, eyes international growth opportunities

Cerus' Q1 2024 earnings call highlighted strong financial performance, positive trial results, and reiterated revenue guidance. The company is focused on achieving breakeven non-GAAP adjusted EBITDA for the year. Challenges include regulatory progress and working capital adjustments, while opportunities exist in international market expansion and operational optimization.

Cerus excels in Q2 2024, raises revenue guidance amid global expansion

Cerus demonstrates strong financial performance, driven by global adoption of INTERCEPT. Focus on expanding sales in key markets and addressing analyst queries to sustain growth momentum. Future growth prospects look promising with a commitment to transparency and investor engagement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Archer Aviation

Beam Therapeutics

Ginkgo Bioworks Holdings

Intellia Therapeutics

Invitae

Verve Therapeutics

Cathie Wood's ARK Innovation ETF isn't afraid to go against Wall Street and the S&P 500. But in some cases, the consensus agrees with the famed ETF manager.

Analysts Agree These 8 Cathie Wood Stock Picks Will Soar In 2024

Cerus Corporation (NASDAQ:CERS ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President & Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Conference Call Participants Operator Good day and thank you for standing by. Welcome to Cerus Corporation Second Quarter 2023 Earnings Conference Call.

Cerus Corporation (CERS) Q3 2023 Earnings Call Transcript

Cerus (CERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.05 per share a year ago.

Cerus (CERS) Reports Q3 Loss, Lags Revenue Estimates

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023. Recent highlights include: Third quarter 2023 total revenue of $47.3 million was comprised of total product revenue of $39.8 million and government contract revenue of $7.5 million. Completed Phase 3 ReCePI study enrollment in cardiovascular surgery patients, with top-line data readout on track for Q1 2024. Attended first in-person AABB Annual Meet.

Cerus Corporation Announces Third Quarter 2023 Financial Results

DALLAS--(BUSINESS WIRE)--Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today announced that it has entered into an agreement with Cerus Corporation (NASDAQ: CERS) to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT® Fibrinogen Complex, or “IFC”) via the Bloodbuy online marketplace. Bloodbuy's flagship cloud-based platform connect.

Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2023 financial results will be released on Thursday, November 2, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit th.

Cerus Corporation to Release Third Quarter 2023 Financial Results on November 2, 2023

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2023 AABB Annual Meeting, taking place in Nashville, TN from October 14 through October 17. This year's AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies. The following is a select list of presentations and abstracts of interest for Cerus. All presentation times are.

Cerus Corporation Announces Workshop and Abstracts at the 2023 AABB Annual Meeting

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will focus on sustaining and evolving the talent and organizational structure to support the future of the business as the leader in safeguarding the global blood supply. Ms. Goodman will also serve as a member of the Company's Executive Leadership Team. “We are excited to welcome Alicia to the Cerus team.

Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus' chief financial officer, is scheduled to participate at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, at 10:30 a.m. EST. A live webcast of the fireside chat will be available at https://wsw.com/webcast/cantor19/cers/2090781. A replay will be available for 90 days after the event. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood s.

Cerus Corporation to Participate in the 2023 Cantor Global Healthcare Conference

Adaptive Biotechnologies

Holley

Lucid Group

908 Devices

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Stocks Wall Street and ARK's Cathie Wood Love Are Trading Under $10 With Huge Upside Potential

Genius Sports

Cathie Wood's ARK Funds Are Loading Up on These 5 Red-Hot Stocks Trading Under $10

Cerus (CERS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.05 per share a year ago.

Cerus (CERS) Reports Q2 Loss, Lags Revenue Estimates

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2023. Recent highlights include: Second quarter 2023 total revenue of $47.7 million was comprised of total product revenue of $38.9 million and government contract revenue of $8.9 million. Received positive feedback for INTERCEPT Red Blood Cells CE Mark submission in clarification meeting with EU competent authority, the Dutch Medicines Evaluation Board (CBG.

Cerus Corporation Announces Second Quarter 2023 Financial Results

Rocket Lab USA

SoFi Technologies

Cathie Wood's ARK Funds Include 5 ‘Strong Buy' Stocks Under $10 With Huge Upside Potential

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2023 financial results will be released on Wednesday, August 2, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit th.

Cerus Corporation to Release Second Quarter 2023 Financial Results on August 2, 2023

DISH Network

While Most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the amount of shares they can buy.

5 Stocks Under $10 With Massive Upside Potential and ARK's Cathie Wood Loves Two of Them

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and a lunch symposium at the 33rd Regional International Society of Blood Transfusion (ISBT) Congress, taking place in Gothenburg, Sweden, from June 17 through June 21. Transfusion medicine experts and professionals from around the world attend the ISBT Congress. This year marks the first time the conference has taken place in person since 2019. The following is a select list of presentati.

Cerus Corporation Announces Symposium and Abstracts at the 33rd Regional ISBT Congress

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2023. In 2005, the World Health Assembly designated June 14 as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. For 2023, the focus of this day is on those patients who rely on blood products over their lifetime, and the donors who make this possible, with the slogan “Give blood, g.

Cerus Corporation Celebrates World Blood Donor Day 2023

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that it has been awarded an additional $8.7 million contract amendment to the original $9.1 million contract by the U.S. Department of Defense (DoD) Industrial Base Analysis and Sustainment (IBAS) program for the development of pathogen reduced, lyophilized cryoprecipitate (“LyoCryo”) to treat bleeding due to trauma. Cerus' LyoCryo product is being designed for shelf stability, rapid availability, and portability.

Cerus Corporation Announces Follow-on Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate

Today, we put medical device concern Cerus Corporation in the spotlight. Cerus has some current challenges, which management believes are temporary.  Sales growth is projected to accelerate significantly in FY2024.

Cerus Corporation: Cash Burn Remains Concerning

Cerus Corporation (NASDAQ:CERS ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Jessica Hanover – Vice President-Corporate Affairs Obi Greenman – President and Chief Executive Officer Vivek Jayaraman – Chief Operating Officer Kevin Green – Chief Financial Officer Conference Call Participants Brandon Folkes – Cantor Fitzgerald Matt Blackman – Stifel Operator Good day, and welcome to the Cerus Corporation's First Quarter 2023 Earnings Conference Call. At this time all participants are in a listen-only mode.

Cerus Corporation (CERS) Q1 2023 Earnings Call Transcript

Cerus (CERS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago.

Cerus (CERS) Reports Q1 Loss, Lags Revenue Estimates

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2023. Recent highlights include: First quarter 2023 total revenue of $38.5 million was comprised of (in thousands, except %):                 Three Months Ended           March 31, Change     2023     2022   $   % Product Revenue $ 30,974 $ 37,444 $ (6,470 ) -17 % Government Contract Revenue   7,502   5,576   1,926   35 % Total Revenue $ 38,476 $ 43,020 $ (4.

Cerus Corporation Announces First Quarter 2023 Financial Results

Block

UiPath

Roku

Shopify

Cathie Wood invests in speculative stocks that don't always pan out, as 2022 showed. The chief of Ark Investment Management watched her firm outperform in 2021, though last year saw a sharp deceleration in interest in various hough-growth names.

7 Best Cathie Wood Stocks for Your May 2023 Buy List

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2023 financial results will be released on Thursday, May 4, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.

News for Cerus Stock (CERS)